Suppr超能文献

小儿脑放射性坏死的治疗:一项系统综述

Treatment of pediatric cerebral radiation necrosis: a systematic review.

作者信息

Drezner N, Hardy K K, Wells E, Vezina G, Ho C Y, Packer R J, Hwang E I

机构信息

Brain Tumor Institute and Center for Cancer and Blood Disorders, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC, 20010, USA.

Center for Neurosciences and Behavioral Medicine, Neuropsychology Division, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC, 20010, USA.

出版信息

J Neurooncol. 2016 Oct;130(1):141-148. doi: 10.1007/s11060-016-2219-5. Epub 2016 Jul 20.

Abstract

Cerebral radiation necrosis (CRN) is a toxicity of radiation therapy that can result in significant, potentially life-threatening neurologic deficits. Treatment for CRN has included surgical resection, corticosteroids, hyperbaric oxygen therapy (HBOT), and bevacizumab, but no consensus approach has been identified. We reviewed the available literature to evaluate efficacy of treatment approaches. Using methods specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines when possible, we conducted searches of Ovid MEDLINE, Embase and Pubmed to identify studies reporting on outcomes for children (≤21 years old) with CRN. Eligible studies from 1990 to 2014 describing central nervous system (CNS) radiation necrosis with details of both treatment and outcomes were included. Eleven studies meeting criteria were identified. Of the nine studies with total patient denominators, 37 of 806 patients developed CRN (incidence = 4.6 %). Patients received treatment courses of steroids alone (n = 13), steroids with bevacizumab (n = 11) or HBOT (n = 12). Patients who failed to respond to steroids were more likely to be older than steroid-responsive patients (p = 0.009). With the exception of steroid-related adverse events, there was only one report of an adverse event (brainstem stroke) potentially attributable to intervention (bevacizumab). Those who received proton beam RT were both younger (p = 0.001) and had a shorter time to development of CRN (p = 0.079). The most common treatment following steroid initiation was addition of bevacizumab or HBOT, with good success and minimal toxicity. However, randomized controlled trials are needed to establish a definitive treatment algorithm that can be applied to children affected by CRN.

摘要

脑放射性坏死(CRN)是放射治疗的一种毒性反应,可导致严重的、可能危及生命的神经功能缺损。CRN的治疗方法包括手术切除、皮质类固醇、高压氧治疗(HBOT)和贝伐单抗,但尚未确定一致的治疗方法。我们回顾了现有文献以评估各种治疗方法的疗效。尽可能采用系统评价和Meta分析的首选报告项目(PRISMA)指南中规定的方法,我们检索了Ovid MEDLINE、Embase和Pubmed,以确定报告CRN患儿(≤21岁)治疗结果的研究。纳入了1990年至2014年描述中枢神经系统(CNS)放射性坏死且有治疗和结果详细信息的符合条件的研究。共确定了11项符合标准的研究。在9项有患者总数分母的研究中,806例患者中有37例发生CRN(发生率=4.6%)。患者接受了单独使用类固醇(n=13)、类固醇联合贝伐单抗(n=11)或HBOT(n=12)的治疗疗程。对类固醇无反应的患者比有反应的患者年龄更大(p=0.009)。除了与类固醇相关的不良事件外,只有1例不良事件(脑干卒中)报告可能归因于干预(贝伐单抗)。接受质子束放疗的患者年龄更小(p=0.001)且发生CRN的时间更短(p=0.079)。类固醇治疗开始后最常见的治疗方法是加用贝伐单抗或HBOT,效果良好且毒性最小。然而,需要进行随机对照试验以建立可应用于受CRN影响儿童的明确治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验